Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  8/28/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 8/28/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Using Cone Beam CT for Head and Neck Cancer
A Pilot Study of Tumor and Critical Normal Tissue Motion in Head and Neck Cancer Using Cone Beam CT
Status: Enrolling
Updated:  8/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study Using Cone Beam CT for Head and Neck Cancer
A Pilot Study of Tumor and Critical Normal Tissue Motion in Head and Neck Cancer Using Cone Beam CT
Status: Enrolling
Updated: 8/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Status: Enrolling
Updated:  8/28/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors
Status: Enrolling
Updated: 8/28/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets
Status: Enrolling
Updated:  8/28/2015
Beckman Laser Institute
mi
from
Irvine, CA
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets
Status: Enrolling
Updated: 8/28/2015
Beckman Laser Institute
mi
from
Irvine, CA
Click here to add this to my saved trials
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets
Status: Enrolling
Updated:  8/28/2015
Gottschalk Medical Plaza, 1 Medical Plaza Drive
mi
from
Irvine, CA
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets
Status: Enrolling
Updated: 8/28/2015
Gottschalk Medical Plaza, 1 Medical Plaza Drive
mi
from
Irvine, CA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Northeast Alabama Regional Medical Center
mi
from
Anniston, AL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Northeast Alabama Regional Medical Center
mi
from
Anniston, AL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Naval Medical Center - San Diego
mi
from
San Diego, CA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Naval Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - San Diego
mi
from
San Diego, CA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Lombardi Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Lombardi Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Walter Reed Army Medical Center
mi
from
Washington,
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Washington, DC
mi
from
Washington,
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Washington, DC
mi
from
Washington,
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Broward General Medical Center
mi
from
Fort Lauderdale, FL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Broward General Medical Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Memorial Regional Cancer Center at Memorial Regional Hospital
mi
from
Hollywood, FL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Memorial Regional Cancer Center at Memorial Regional Hospital
mi
from
Hollywood, FL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
MBCCOP - University of Illinois at Chicago
mi
from
Chicago, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
MBCCOP - University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Lagrange Oncology Associates
mi
from
La Grange, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Lagrange Oncology Associates
mi
from
La Grange, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
West Suburban Center for Cancer Care
mi
from
River Forest, IL
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
West Suburban Center for Cancer Care
mi
from
River Forest, IL
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Fort Wayne Medical Oncology and Hematology, Incorporated
mi
from
Fort Wayne, IN
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Fort Wayne Medical Oncology and Hematology, Incorporated
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Baptist Hospital East - Louisville
mi
from
Louisville, KY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Baptist Hospital East - Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Greenebaum Cancer Center at University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
UMASS Memorial Cancer Center - University Campus
mi
from
Worcester, MA
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
UMASS Memorial Cancer Center - University Campus
mi
from
Worcester, MA
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph
mi
from
Saint Joseph, MI
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Ellis Fischel Cancer Center at University of Missouri - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Missouri Baptist Cancer Center
mi
from
Saint Louis, MO
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Missouri Baptist Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Las Vegas
mi
from
Las Vegas, NV
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Las Vegas
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
New Hampshire Oncology - Hematology, PA - Hooksett
mi
from
Hooksett, NH
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
New Hampshire Oncology - Hematology, PA - Hooksett
mi
from
Hooksett, NH
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Cancer Institute of New Jersey at the Cooper University Hospital
mi
from
Camden, NJ
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Cancer Institute of New Jersey at the Cooper University Hospital
mi
from
Camden, NJ
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
East Syracuse, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
East Syracuse, NY
Click here to add this to my saved trials
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated:  8/28/2015
Elmhurst Hospital Center
mi
from
Elmhurst, NY
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Evaluation Of Novel Therapeutic Agents (Celecoxib: NSC # 719627) Against Breast Cancer: An Innovative Randomized Phase II Trial Design
Status: Enrolling
Updated: 8/28/2015
Elmhurst Hospital Center
mi
from
Elmhurst, NY
Click here to add this to my saved trials